H.C. Wainwright lowered the firm’s price target on Karyopharm (KPTI) to $8 from $15 and keeps a Buy rating on the shares. Following the most recently reported clinical results, the firm lowered its probability of approval for Xpovio in myelofibrosis to 35% from 65%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Announces Financing and Positive SENTRY Trial Results
- Karyopharm up 23% after Phase 3 SENTRY trial meets first co-primary endpoint
- Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint
- Karyopharm announces $30M private placement
- Karyopharm initiated with a Buy at Rodman & Renshaw